4-[2-(5-氯-2-甲氧基苯甲酰氨基)乙基]苯磺酰胺

中文名称:

4-[2-(5-氯-2-甲氧基苯甲酰氨基)乙基]苯磺酰胺

中文同义词:

4-[2-(2-甲氧基-5-氯苯甲酰胺基)乙基]苯磺酰胺;5-氯-2-甲氧基-N-[2-对氨磺酰苯基)乙基]苯甲酰氨;N-{2-[4-(氨磺酰基)苯基]乙基}-5-氯-2-甲氧基苯甲酰胺;格列本脲中间体;格列本脲相关物质A;格列本脲USP RC A;格列本脲(优降糖)杂质A;4-[2-(5-氯-2-甲氧基-苯甲酰氨基)乙基]苯磺酰胺

英文名称:

4-(2-(5-Chloro-2-methoxybenzamido)ethyl)benzenesulfamide

英文同义词:

4-(2-(5-Chloro-2-methoxybenzamido)ethyl)benzenesulfamide;Glyburide Related Compound A (25 mg) (5-chloro-2-methoxy-N-[2-(4-sulfamoylphenyl)ethyl]benzamide);4-[2-(2-Methoxy-5-chlorobenzene-1-carboxaMido)ethyl]benzenesulfonaMide;5-Chloro-N-(p-sulfaMoylphenethyl)-o-anisaMide;5-Chloro-2-Methoxy-N-(4-sulfaMoylphenethyl)benzaMide;GlibenclaMide (Glyburide) IMpurity A;Glyburide Related CoMpound A;Glyburide Related Compound A (25 mg) (4-[2-(5-chloro-2-methoxybenzamido)ethyl]benzenesulfonamide)

CAS号:

16673-34-0

分子式:

C16H17ClN2O4S

分子量:

368.84

EINECS号:

240-722-5

相关类别:

磺胺类药物/亚磺酰胺;磺胺类药物;亚磺酰胺;中间体;有机化学;Pharmaceuticals;Organic Building Blocks;Sulfonamides/Sulfinamides;Sulfur Compounds;Aromatics;Intermediates Fine Chemicals;Aromatics,Pharmaceuticals;Building Blocks;Chemical Synthesis;Organic Building Blocks;Sulfur Compounds

Mol文件:

16673-34-0.mol

熔点 

209-214 °C

密度 

1.356±0.06 g/cm3(Predicted)

储存条件 

2-8°C

形态

neat

酸度系数(pKa)

10.14±0.10(Predicted)

CAS 数据库

16673-34-0(CAS DataBase Reference)

生物活性

NLRP3 Inflammasome Inhibitor I是合成格列本脲的中间底物，它是NLRP3 inflammasome的抑制剂。

靶点

Target Value NLRP3 inflammasome ()

Target

Value

NLRP3 inflammasome ()

体内研究

NLRP3-IN-2 is well tolerated with no effects on the glucose levels in vivo. NLRP3-IN-2 (100 mg/kg) treatment in a model of AMI due to ischemia+reperfusion significantly inhibits the activity of inflammasome (caspase-1) in the heart by 90% (P<0.01) and reduced infarct size, measured at pathology (by >40%, P<0.01) and with troponin I levels (by >70%, P<0.01) . Animal Model: Experimental acute myocardial infarction (AMI) model in mice. Dosage: 100 mg/kg. Administration: Intraperitoneal administration 30 minutes prior to surgery, then every 6 hours for 3 additional doses. Result: Led to a significant >90% reduction in caspase-1 activity (reflective of the formation of an active inflammasome) in the heart tissue measured 24 hours after ischemia. Led to a significant reduction in the infarct size measured with TTC (>40% reduction) or troponin I levels (>70% reduction) when compared with vehicle alone.

Animal Model:

Experimental acute myocardial infarction (AMI) model in mice.

Dosage:

100 mg/kg.

Administration:

Intraperitoneal administration 30 minutes prior to surgery, then every 6 hours for 3 additional doses.

Result:

Led to a significant >90% reduction in caspase-1 activity (reflective of the formation of an active inflammasome) in the heart tissue measured 24 hours after ischemia. Led to a significant reduction in the infarct size measured with TTC (>40% reduction) or troponin I levels (>70% reduction) when compared with vehicle alone.

化学性质 

结晶化合物。熔点185-200℃。

用途 

优降糖的中间体。

生产方法 

用水杨酸在光照下以氯气氯化，生成5-氯水杨酸，然后以硫酸二甲酯甲基化得5-氯-2-甲氧基苯甲酸，将后者以氯化亚硫酰氯化，得5-氯-2-甲氧基苯甲酰氯，再与苯胺缩合，产物为N-苯乙基-5-氯-2-甲氧基苯甲酰胺，进而以氯磺酸氯磺化、氨水胺化制得该品。

危险品标志 

T

危险类别码 

23-24-25

安全说明 

24/25

WGK Germany 

1

海关编码 

2935909550